<DOC>
	<DOC>NCT02500043</DOC>
	<brief_summary>The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.</brief_summary>
	<brief_title>Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer</brief_title>
	<detailed_description>This is a multinational, double-blind, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of TAS-102 plus BSC versus placebo plus BSC in patients with metastatic gastric cancer who have previously received at least 2 prior regimens for advanced disease. Eligible patients will be centrally randomized (2:1) to TAS-102 + BSC (experimental arm) or placebo + BSC (control arm).</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1. Has histologically confirmed nonresectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction. 2. Has previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy. 3. Has measureable or nonmeasurable disease as defined by RECIST 1.1 criteria. 4. Is able to take medications orally (ie, no feeding tube). 5. Has an ECOG performance status of 0 or 1. 6. Has adequate organ function as defined by protocol defined labs. 7. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control. 1. Has certain serious illnesses or medical conditions 2. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent within the specified time frames prior to study drug administration. 3. Has previously received TAS102. 4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies. 5. Is a pregnant or lactating female.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Metastatic Gastric Cancer</keyword>
</DOC>